KOREA WHO

Huh Eun-chul is the President and CEO of GC Green Cross.

After two attempts, he succeeded in launching sales of the blood-derived product “Aliglo,” a treatment for immunodeficiency, in the United States, marking the company’s full-scale overseas expansion.

He is also strengthening efforts in developing vaccines and treatments for rare diseases, broadening GC Green Cross’s business portfolio.

Huh was born on February 23, 1972, in Seoul, as the second son of former Green Cross Chairman Huh Young-sup and his wife Jung In-ae. His grandfather is Huh Chae-kyung, founder of Hanil Cement.

He graduated from Youngdong High School and Seoul National University with a degree in Food Science and Technology, and went on to earn a master’s degree in Biochemical Engineering at Seoul National University. He later completed a Ph.D. program in Food Science at Cornell University in the United States.

Huh began his career at Green Cross in the Corporate Planning Office and worked mainly in the research and development (R&D) division. He advanced through roles as Managing Director and Senior Managing Director of R&D Planning, then broadened his responsibilities as Chief Technology Officer (CTO), before becoming Head of Corporate Strategy, overseeing company-wide management.

He initially shared leadership under a co-CEO system with Vice Chairman Cho Soon-tae, but now serves as the sole CEO of GC Green Cross after Cho’s departure.

Huh is a devout Christian.

He dislikes rigid formalities, prefers a horizontal organizational culture, and is regarded among employees as an icon of youthful energy and communication.

#GCGreenCross #HuhEunchul #biopharma #immunodeficiency #Aliglo #rareDisease #vaccine #biotechnology #globalExpansion #ChristianLeadership